| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-07-08 | volasertib | acute myeloid leukemia (AML) |
2 | Boehringer Ingelheim (Germany) | Cancer - Oncology |
| 2014-07-08 | ladostigil [(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate] | mild cognitive impairment |
2b | Avraham Pharmaceuticals (Israel) | CNS diseases - Neurodegenerative diseases |
| 2014-07-08 | DS107E (DGLA cream) | atopic dermatitis |
2 | Dignity Sciences (Ireland) | Dermatological diseases - Immunological diseases - Inflammatory diseases |
| 2014-07-08 | CB-03-01 (cortexolone 17alpha-propionate) | acne |
2 | Cosmo Pharmaceuticals (Italy) | Dermatological diseases |
| 2014-07-07 | mGlu5 NAM (negative allosteric modulator) drug candidates | preclinical | Heptares Therapeutics (UK) | CNS diseases | |
| 2014-07-07 | Rayaldee™ ( calcifediol - vitamin D prohormone) | adjunctive therapy for the prevention of skeletal-related events (SREs) in patients with bone metastases undergoing anti-resorptive therapy |
1 | OPKO Health (USA - FL) | Cancer - Oncology |
| 2014-07-03 | SMT19969 | Clostridium difficile infection |
2 | Summit (UK) | Infectious diseases |
| 2014-07-02 | MEDI8897 | respiratory syncytial virus (RSV) infections in young, at risk children |
1 | Medimmune (USA - global biologics arm of AstraZeneca (UK), AIMM Therapeutics (The Netherlands) | Infectious diseases |
| 2014-07-01 | Prophage autologous cancer vaccine | newly diagnosed glioblastoma multiforme |
2 | Agenus (USA) | Cancer - Oncology |
| 2014-07-01 | rivipansel | treatment of patients with sickle cell disease who are hospitalized for vaso-occlusive crisis (VOC) |
3 | Pfizer (USA - NY) GlycoMimetics (USA - MA) | Hematologic diseases - Genetic diseases - Rare diseases |
| 2014-07-01 | apatorsen | previously untreated patients with advanced squamous cell lung cancer |
2 | OncoGenex Pharmaceuticals (USA - WA) | Cancer - Oncology |
| 2014-06-27 | Elelyso® (taliglucerase alfa) | Gaucher disease |
Protalix BioTherapeutics (Israel) | Rare diseases | |
| 2014-06-27 | ofatumumab (Arzerra™) | bulky fludarabine-refractory chronic lymphocytic leukaemia (CLL) |
3 | GSK (UK) Genmab (Denmark) | Cancer - Oncology |
| 2014-06-26 | Brintellix® (vortioxetine) | major depression |
Lundbeck (Denmark) Otsuka Pharmaceutical (Japan) | CNS diseases - Mental diseases | |
| 2014-06-26 | RHB-104 | type 1 diabetes |
preclinical | RedHill Biopharma (Israel) | Metabolic diseases |
| 2014-06-26 | HerpV | genital herpes |
2 | Agenus (USA) | Infectious diseases |
| 2014-06-26 | oral TSO (Trichuris suis ova or CNDO-201) | autism spectrum disorder |
1 | Coronado Biosciences (USA) | CNS diseases - Mental diseases - Neurodevelopmental diseases |
| 2014-06-25 | once-a-week formulation of exenatide based on Medusa drug delivery platform | type 2 diabetes |
preclinical | Flamel Technologies (France) | Metabolic diseases |
| 2014-06-25 | eltrombopag (Promacta™/Revolade™) in combination with azacitidine | myelodysplastic syndromes |
3 | GSK (UK) Ligand Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2014-06-25 | optimized formulation of a DC vaccine | hormone-refractory prostate cancer |
preclinical | MediGene (Germany) | Cancer - Oncology |
